Halozyme Therapeutics, Inc.
Income Statement
| Line Item | FY2009 |
|---|---|
| Revenue | $13.7M |
| Cost of Revenue | $311.9K |
| Gross Profit | $13.4M |
| Gross Margin | 97.7% |
| Operating Expenses | |
| Research & Development | $56.6M |
| SG&A Expense | $15.2M |
| Operating Income | $-58.5M |
| Operating Margin | -427.6% |
| Interest Expense | — |
| Pretax Income | — |
| Income Tax Expense | — |
| Net Income | $-58.4M |
| Net Margin | -426.9% |
| EPS (Basic) | $-0.67 |
| EPS (Diluted) | $-0.67 |
| Shares Outstanding (Basic) | — |
| Shares Outstanding (Diluted) | — |
| Dividends Per Share | — |